STOCK TITAN

[Form 4] RAPID MICRO BIOSYSTEMS, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Rapid Micro Biosystems (RPID) reported insider transactions by President & CEO and Director Robert G. Spignesi, Jr. on 10/17/2025. He exercised stock options (code M) for 3,400 and 7,833 shares at an exercise price of $0.75 per share via net exercise. The company withheld 2,072 and 4,774 shares (code F) using the $3.08 closing price to cover the exercise price and taxes, consistent with the 2010 Stock Option and Grant Plan. Following these transactions, he directly owned 974,937 Class A common shares.

Rapid Micro Biosystems (RPID) ha riportato operazioni interne da parte del Presidente e CEO e Direttore Robert G. Spignesi, Jr. il 17/10/2025. Ha esercitato stock options (codice M) per 3.400 e 7.833 azioni a un prezzo di esercizio di $0,75 per azione tramite net exercise. L'azienda ha trattenuto 2.072 e 4.774 azioni (codice F) utilizzando la chiusura di $3,08 per coprire il prezzo di esercizio e le tasse, in conformità con il piano Stock Option and Grant del 2010. A seguito di queste operazioni, lui possiede direttamente 974.937 azioni ordinarie di Classe A.

Rapid Micro Biosystems (RPID) informó sobre operaciones de insider por parte del Presidente y CEO y Director Robert G. Spignesi, Jr. el 17/10/2025. Ejerció opciones sobre acciones (código M) por 3,400 y 7,833 acciones a un precio de ejercicio de $0.75 por acción mediante ejercicio neto. La empresa retuvo 2,072 y 4,774 acciones (código F) utilizando el cierre de $3.08 para cubrir el precio de ejercicio y los impuestos, conforme al Plan de Opciones y Concesiones de 2010. Después de estas transacciones, él poseía directamente 974,937 acciones comunes de Clase A.

Rapid Micro Biosystems (RPID)2025년 10월 17일에 사장 겸 CEO이자 이사인 Robert G. Spignesi, Jr.의 내부자 거래를 보고했습니다. 그는 3,400주와 7,833주를 실행 가격 $0.75로 주식 옵션(code M)을 행사했습니다. 순행사를 통해. 회사는 2,072주와 4,774주를(code F)을 보유 지불하기 위해 $3.08 종가로 행사가 및 세금을 충당했습니다. 이는 2010년 주식 옵션 및 양도 계획에 따른 것입니다. 이 거래 후 그는 직접 974,937주 Class A 보통주를 보유하게 되었습니다.

Rapid Micro Biosystems (RPID) a annoncé des transactions d'initiés par le président et PDG et administrateur Robert G. Spignesi, Jr. le 17/10/2025. Il a exercé des options d'achat d'actions (code M) pour 3 400 et 7 833 actions à un prix d'exercice de 0,75 $ par action via l'exercice net. L'entreprise a retenu 2 072 et 4 774 actions (code F) en utilisant la clôture de 3,08 $ pour couvrir le prix d'exercice et les impôts, conformément au Plan Stock Option et Grant de 2010. Suite à ces transactions, il possédait directement 974 937 actions ordinaires de classe A.

Rapid Micro Biosystems (RPID) meldete Insider-Transaktionen des Präsidenten & CEO sowie Direktors Robert G. Spignesi, Jr. am 17.10.2025. Er übte Aktienoptionen (Code M) für 3.400 und 7.833 Aktien zu einem Ausübungspreis von $0,75 pro Aktie durch Net-Exercise aus. Das Unternehmen behielt 2.072 und 4.774 Aktien (Code F) unter Verwendung des Schlusskurses von $3,08, um den Ausübungspreis und Steuern zu decken, gemäß dem Stock Option and Grant Plan von 2010. Nach diesen Transaktionen besaß er direkt 974.937 Class-A-Stammaktien.

Rapid Micro Biosystems (RPID) أبلغت عن معاملات داخلية من قبل الرئيس والمدير التنفيذي وعضو مجلس الإدارة روبرت ج. سبينجيزي جونيور في 17/10/2025. مارس خيارات شراء أسهم (رمز M) لـ 3,400 و 7,833 سهمًا بسعر إ ejercer $0.75 للسهم عن طريق التمرين الصافي. احتفظت الشركة بـ 2,072 و 4,774 سهمًا (رمز F) باستخدام سعر إغلاق $3.08 لتغطية سعر التمرين والضرائب، وفقًا لخطة خيارات الأسهم والمنح لعام 2010. عقب هذه المعاملات، كان يملك مباشرةً 974,937 سهمًا عاديًا من الفئة أ.

Rapid Micro Biosystems (RPID) 报告了由董事长兼首席执行官 Robert G. Spignesi, Jr. 于 2025/10/17发布的内部人交易。他以净额行权方式行使了代码为 M 的股票期权,数量为 3,400 股和 7,833 股,行权价为每股 $0.75。公司以收盘价 $3.08 代扣了 2,072 股和 4,774 股(代码 F),用于覆盖行权价及税费,符合 2010 年股票期权与授予计划。经这些交易后,他直接持有 974,937 股 A 类普通股。

Positive
  • None.
Negative
  • None.

Rapid Micro Biosystems (RPID) ha riportato operazioni interne da parte del Presidente e CEO e Direttore Robert G. Spignesi, Jr. il 17/10/2025. Ha esercitato stock options (codice M) per 3.400 e 7.833 azioni a un prezzo di esercizio di $0,75 per azione tramite net exercise. L'azienda ha trattenuto 2.072 e 4.774 azioni (codice F) utilizzando la chiusura di $3,08 per coprire il prezzo di esercizio e le tasse, in conformità con il piano Stock Option and Grant del 2010. A seguito di queste operazioni, lui possiede direttamente 974.937 azioni ordinarie di Classe A.

Rapid Micro Biosystems (RPID) informó sobre operaciones de insider por parte del Presidente y CEO y Director Robert G. Spignesi, Jr. el 17/10/2025. Ejerció opciones sobre acciones (código M) por 3,400 y 7,833 acciones a un precio de ejercicio de $0.75 por acción mediante ejercicio neto. La empresa retuvo 2,072 y 4,774 acciones (código F) utilizando el cierre de $3.08 para cubrir el precio de ejercicio y los impuestos, conforme al Plan de Opciones y Concesiones de 2010. Después de estas transacciones, él poseía directamente 974,937 acciones comunes de Clase A.

Rapid Micro Biosystems (RPID)2025년 10월 17일에 사장 겸 CEO이자 이사인 Robert G. Spignesi, Jr.의 내부자 거래를 보고했습니다. 그는 3,400주와 7,833주를 실행 가격 $0.75로 주식 옵션(code M)을 행사했습니다. 순행사를 통해. 회사는 2,072주와 4,774주를(code F)을 보유 지불하기 위해 $3.08 종가로 행사가 및 세금을 충당했습니다. 이는 2010년 주식 옵션 및 양도 계획에 따른 것입니다. 이 거래 후 그는 직접 974,937주 Class A 보통주를 보유하게 되었습니다.

Rapid Micro Biosystems (RPID) a annoncé des transactions d'initiés par le président et PDG et administrateur Robert G. Spignesi, Jr. le 17/10/2025. Il a exercé des options d'achat d'actions (code M) pour 3 400 et 7 833 actions à un prix d'exercice de 0,75 $ par action via l'exercice net. L'entreprise a retenu 2 072 et 4 774 actions (code F) en utilisant la clôture de 3,08 $ pour couvrir le prix d'exercice et les impôts, conformément au Plan Stock Option et Grant de 2010. Suite à ces transactions, il possédait directement 974 937 actions ordinaires de classe A.

Rapid Micro Biosystems (RPID) meldete Insider-Transaktionen des Präsidenten & CEO sowie Direktors Robert G. Spignesi, Jr. am 17.10.2025. Er übte Aktienoptionen (Code M) für 3.400 und 7.833 Aktien zu einem Ausübungspreis von $0,75 pro Aktie durch Net-Exercise aus. Das Unternehmen behielt 2.072 und 4.774 Aktien (Code F) unter Verwendung des Schlusskurses von $3,08, um den Ausübungspreis und Steuern zu decken, gemäß dem Stock Option and Grant Plan von 2010. Nach diesen Transaktionen besaß er direkt 974.937 Class-A-Stammaktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Spignesi Robert G. Jr.

(Last) (First) (Middle)
C/O RAPID MICRO BIOSYSTEMS, INC.
25 HARTWELL AVENUE

(Street)
LEXINGTON MA 02421

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RAPID MICRO BIOSYSTEMS, INC. [ RPID ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/17/2025 M 3,400 A $0.75 973,950 D
Class A Common Stock 10/17/2025 F 2,072(1) D $3.08 971,878 D
Class A Common Stock 10/17/2025 M 7,833 A $0.75 979,711 D
Class A Common Stock 10/17/2025 F 4,774(2) D $3.08 974,937 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.75 10/17/2025 M 3,400 (3) 10/22/2025 Class A Common Stock 3,400 $0 0 D
Stock Option (Right to Buy) $0.75 10/17/2025 M 7,833 (3) 10/22/2025 Class A Common Stock 7,833 $0 0 D
Explanation of Responses:
1. Represents a "net exercise" of outstanding stock options. The reporting person received 1,328 shares of common stock on net exercise of option to purchase 3,400 shares of common stock. The Company withheld 2,072 shares of common stock underlying the option for payment of the exercise price and tax withholdings, using the closing stock price on October 17, 2025 of $3.08, pursuant to the terms of the 2010 Stock Option and Grant Plan.
2. Represents a "net exercise" of outstanding stock options. The reporting person received 3,059 shares of common stock on net exercise of option to purchase 7,833 shares of common stock. The Company withheld 4,774 shares of common stock underlying the option for payment of the exercise price and tax withholdings, using the closing stock price on October 17, 2025 of $3.08, pursuant to the terms of the 2010 Stock Option and Grant Plan.
3. The option is fully vested and exercisable.
Remarks:
/s/ Sean M. Wirtjes, Attorney-in-Fact for Robert G. Spignesi, Jr. 10/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RPID’s CEO report on Form 4?

He executed two option exercises (code M) for 3,400 and 7,833 shares at $0.75 on 10/17/2025, with share withholding for taxes and exercise price.

How many shares were withheld to cover costs?

The company withheld 2,072 and 4,774 shares (code F) using the $3.08 closing price on 10/17/2025.

How many shares does the CEO own after these transactions?

He directly owned 974,937 shares of Class A common stock following the reported transactions.

What is the exercise price of the options?

The stock options carried an exercise price of $0.75 per share.

Were the options vested?

Yes. The filing states the option is fully vested and exercisable.

What pricing was used for withholding shares?

The $3.08 closing stock price on 10/17/2025 was used for payment of the exercise price and tax withholdings.

What is the reporting person’s role at RPID?

Robert G. Spignesi, Jr. is President & CEO and a Director.

Rapid Micro Biosystems, Inc.

NASDAQ:RPID

RPID Rankings

RPID Latest News

RPID Latest SEC Filings

RPID Stock Data

138.82M
35.20M
9.6%
59.55%
0.77%
Medical Devices
Laboratory Analytical Instruments
Link
United States
LEXINGTON